ATE386748T1 - Verwendung von liganden von cd52 antigen zur behandlung von soliden tumoren und von knochenkrebserkrankungen - Google Patents

Verwendung von liganden von cd52 antigen zur behandlung von soliden tumoren und von knochenkrebserkrankungen

Info

Publication number
ATE386748T1
ATE386748T1 AT03029464T AT03029464T ATE386748T1 AT E386748 T1 ATE386748 T1 AT E386748T1 AT 03029464 T AT03029464 T AT 03029464T AT 03029464 T AT03029464 T AT 03029464T AT E386748 T1 ATE386748 T1 AT E386748T1
Authority
AT
Austria
Prior art keywords
solid tumors
bone cancer
cancer diseases
treat solid
antigen ligands
Prior art date
Application number
AT03029464T
Other languages
English (en)
Inventor
Veit Krenn
Original Assignee
Charite Universitaetsmedizin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charite Universitaetsmedizin filed Critical Charite Universitaetsmedizin
Application granted granted Critical
Publication of ATE386748T1 publication Critical patent/ATE386748T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03029464T 2003-12-19 2003-12-19 Verwendung von liganden von cd52 antigen zur behandlung von soliden tumoren und von knochenkrebserkrankungen ATE386748T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03029464A EP1544213B1 (de) 2003-12-19 2003-12-19 Verwendung von Liganden von CD52 Antigen zur Behandlung von soliden Tumoren und von Knochenkrebserkrankungen

Publications (1)

Publication Number Publication Date
ATE386748T1 true ATE386748T1 (de) 2008-03-15

Family

ID=34486276

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03029464T ATE386748T1 (de) 2003-12-19 2003-12-19 Verwendung von liganden von cd52 antigen zur behandlung von soliden tumoren und von knochenkrebserkrankungen

Country Status (5)

Country Link
US (1) US20070148191A1 (de)
EP (1) EP1544213B1 (de)
AT (1) ATE386748T1 (de)
DE (1) DE60319240D1 (de)
WO (1) WO2005058966A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110212086A1 (en) * 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
US8187601B2 (en) * 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
WO2010027370A1 (en) * 2008-09-08 2010-03-11 The Regents Of The University Of Michigan Compositions and methods for the treatment of solid tumor cancers
SG175127A1 (en) * 2009-04-13 2011-11-28 Apceth Gmbh & Co Kg Engineered mesenchymal stem cells and method of using same to treat tumors
AU2021327387A1 (en) 2020-08-21 2023-05-04 Genzyme Corporation Fgfr3 antibodies and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US20030124127A1 (en) * 2001-12-06 2003-07-03 Lijun Yang Targeting leukemia cells
WO2003080671A1 (en) * 2002-03-21 2003-10-02 Komed Co., Ltd. Anti-rank monoclonal antibodies and pharmaceutical composition containing the same
US20070037825A1 (en) * 2002-07-19 2007-02-15 Janina Baranowska-Kortylewicz Enhancing the effect of radioimmunotherapy in the treatment of tumors
US20040191328A1 (en) * 2002-12-31 2004-09-30 Warrell Raymond P. Combination of gallium compounds with nonchemotherapeutic anticancer agents in the treatment of neoplasia

Also Published As

Publication number Publication date
EP1544213A1 (de) 2005-06-22
WO2005058966A3 (en) 2005-09-01
WO2005058966A2 (en) 2005-06-30
EP1544213B1 (de) 2008-02-20
US20070148191A1 (en) 2007-06-28
DE60319240D1 (de) 2008-04-03

Similar Documents

Publication Publication Date Title
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
ATE516818T1 (de) Auristatin-konjugate und ihre verwendung zur behandlung von krebs, einer autoimmunkranheit oder einer infektionskrankheit
ATE345130T1 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
ATE468331T1 (de) Neue cyanopyridine-derivate zur behandlung von krebs und anderer erkrankungen
ATE410446T1 (de) Zusammensetzungen zur behandlung und diagnose von eierstockkrebs
ATE422358T1 (de) Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen
DE602006014843D1 (de) Verwendung von hif 1alfa modulatoren zur behandlung von krebs
TNSN05300A1 (en) Treatment with anti-vegf antibodies
DE60306505D1 (de) Verfahren zur behandlung von brustdrüsenerkrankungen
DE602005015687D1 (de) Phospholipid-analoga für die behandlung von krebs
WO2003087831A3 (en) Proteins involved in breast cancer
ATE531688T1 (de) Verbindungen zur modulation des rage-rezeptors
WO2005023202A3 (en) Tumor suppressor lkb1 kinase directly activates amp-activated kinase
DE602004020266D1 (de) Therapeutische und diagnostische anti-hsp 70-antikörper
ATE421324T1 (de) Verwendung von isochinolin-derivaten zur behandlung von krebs und erkrankungen im zusammenhang mit map kinase
ATE386748T1 (de) Verwendung von liganden von cd52 antigen zur behandlung von soliden tumoren und von knochenkrebserkrankungen
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
ATE439130T1 (de) Epothilonderivat zur behandlung von hepatoma und anderen krebserkrankungen
DE60224429D1 (de) Pharmazeutische zusammensetzung zur verwendung bei der behandlung von malignen erkrankungen, umfassend eine kombination aus bisphosphonaten, einem cox-2 inhibitor und einem taxol
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE384520T1 (de) Kombinierte verwendung von einem fibrat und von orlistat zur behandlung von obesitas
ATE329597T1 (de) Die verwendung von einer 4- pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
DE602004003829D1 (de) 2-ä4-(phenylamino)-piperidin-1-ylü-n-phenyl-acetamid derivate und verwandte verbindungen als neuropeptid y5 (npy5) liganden zur behandlung von fettleibigkeit
EP1646385A4 (de) Verwendung von benzothiopenen zur behandlung und prävention von prostatakrebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties